Selenium Nanoparticles with Prodigiosin Rescue Hippocampal Damage Associated with Epileptic Seizures Induced by Pentylenetetrazole in Rats.
apoptosis
epilepsy
neuroinflammation
neurotransmission
oxidative stress
prodigiosin
selenium nanoparticles
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
23 Feb 2022
23 Feb 2022
Historique:
received:
20
11
2021
revised:
31
01
2022
accepted:
13
02
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
Prodigiosin (PDG) is a red pigment synthesized by bacterial species with important pharmaceutical and biological activities. Here, we investigated the neuroprotective and anticonvulsant activities of green biosynthesized selenium formulations with PDG (SeNPs-PDG) versus pentylenetetrazole (PTZ)-induced epileptic seizures. Rats were assigned into six experimental groups: control; PTZ (60 mg/kg, epileptic model); sodium valproate (200 mg/kg) + PTZ; PDG (300 mg/kg) + PTZ; sodium selenite (0.5 mg/kg) + PTZ; and SeNPs-PDG (0.5 mg/kg) + PTZ. The treatment duration is extended to 28 days. SeNPs-PDG pre-treatment delayed seizures onset and reduced duration upon PTZ injection. Additionally, SeNPs-PDG enhanced the antioxidant capacity of hippocampal tissue by activating the expression of nuclear factor erythroid 2-related factor 2 and innate antioxidants (glutathione and glutathione derivatives, in addition to superoxide dismutase and catalase) and decreasing the levels of pro-oxidants (lipoperoxidation products and nitric oxide). SeNPs-PDG administration inhibited inflammatory reactions associated with epileptic seizure development by suppressing the production and activity of glial fibrillary acidic protein and pro-inflammatory mediators, including interleukin-1 beta, tumor necrosis factor-alpha, cyclooxygenase-2, inducible nitric oxide synthase, and nuclear factor kappa B. Moreover, SeNPs-PDG protected against hippocampal cell loss following PTZ injection by decreasing the levels of cytosolic cytochrome c, Bax, and caspase-3 and enhancing the expression of anti-apoptotic Bcl-2. Interestingly, SeNPs-PDG restored the PTZ-induced imbalance between excitatory and inhibitory amino acids and improved monoaminergic and cholinergic transmission. These promising antioxidative, anti-inflammatory, anti-apoptotic, and neuromodulatory activities indicate that SeNPs-PDG might serve as a naturally derived anticonvulsant agent.
Sections du résumé
BACKGROUND
BACKGROUND
Prodigiosin (PDG) is a red pigment synthesized by bacterial species with important pharmaceutical and biological activities. Here, we investigated the neuroprotective and anticonvulsant activities of green biosynthesized selenium formulations with PDG (SeNPs-PDG) versus pentylenetetrazole (PTZ)-induced epileptic seizures.
METHODS
METHODS
Rats were assigned into six experimental groups: control; PTZ (60 mg/kg, epileptic model); sodium valproate (200 mg/kg) + PTZ; PDG (300 mg/kg) + PTZ; sodium selenite (0.5 mg/kg) + PTZ; and SeNPs-PDG (0.5 mg/kg) + PTZ. The treatment duration is extended to 28 days.
RESULTS
RESULTS
SeNPs-PDG pre-treatment delayed seizures onset and reduced duration upon PTZ injection. Additionally, SeNPs-PDG enhanced the antioxidant capacity of hippocampal tissue by activating the expression of nuclear factor erythroid 2-related factor 2 and innate antioxidants (glutathione and glutathione derivatives, in addition to superoxide dismutase and catalase) and decreasing the levels of pro-oxidants (lipoperoxidation products and nitric oxide). SeNPs-PDG administration inhibited inflammatory reactions associated with epileptic seizure development by suppressing the production and activity of glial fibrillary acidic protein and pro-inflammatory mediators, including interleukin-1 beta, tumor necrosis factor-alpha, cyclooxygenase-2, inducible nitric oxide synthase, and nuclear factor kappa B. Moreover, SeNPs-PDG protected against hippocampal cell loss following PTZ injection by decreasing the levels of cytosolic cytochrome c, Bax, and caspase-3 and enhancing the expression of anti-apoptotic Bcl-2. Interestingly, SeNPs-PDG restored the PTZ-induced imbalance between excitatory and inhibitory amino acids and improved monoaminergic and cholinergic transmission.
CONCLUSIONS
CONCLUSIONS
These promising antioxidative, anti-inflammatory, anti-apoptotic, and neuromodulatory activities indicate that SeNPs-PDG might serve as a naturally derived anticonvulsant agent.
Identifiants
pubmed: 35336729
pii: biology11030354
doi: 10.3390/biology11030354
pmc: PMC8945383
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Seizure. 2014 Mar;23(3):184-90
pubmed: 24315662
Brain Res. 2000 Feb 7;855(1):186-91
pubmed: 10650149
PLoS One. 2019 Jun 13;14(6):e0216737
pubmed: 31194753
Life Sci. 2013 Sep 17;93(9-11):393-400
pubmed: 23911670
J Complement Integr Med. 2018 Mar 23;15(3):
pubmed: 29570450
Epilepsy Res. 2019 Aug;154:90-96
pubmed: 31112902
Neurotox Res. 2020 Jan;37(1):77-92
pubmed: 31332714
Ecotoxicol Environ Saf. 2020 Jun 1;195:110479
pubmed: 32199213
J Biol Chem. 1998 Jun 19;273(25):15846-53
pubmed: 9624185
Neuropsychiatr Dis Treat. 2016 Jun 17;12:1425-34
pubmed: 27382285
Int J Nanomedicine. 2021 Dec 30;16:8447-8464
pubmed: 35002238
J Chromatogr B Biomed Sci Appl. 2000 Sep 15;746(2):297-304
pubmed: 11076082
J Photochem Photobiol B. 2019 Jan;190:98-102
pubmed: 30504054
Curr Neuropharmacol. 2019;17(12):1158-1175
pubmed: 31400269
Int J Nanomedicine. 2020 Aug 24;15:6339-6353
pubmed: 32922005
Int J Mol Sci. 2015 Aug 07;16(8):18348-67
pubmed: 26262608
Epilepsy Behav. 2019 Dec;101(Pt B):106410
pubmed: 31378559
Dose Response. 2020 Aug 3;18(3):1559325820946914
pubmed: 32821254
BMC Neurosci. 2017 Jan 19;18(1):15
pubmed: 28103798
Nat Rev Neurol. 2015 Oct;11(10):567-84
pubmed: 26392380
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
Eur J Med Chem. 2016 Mar 3;110:13-31
pubmed: 26807541
Neurochem Res. 2015 Aug;40(8):1758-66
pubmed: 26160706
J Food Sci Technol. 2018 Jul;55(7):2661-2670
pubmed: 30042582
J Lab Clin Med. 1967 Jul;70(1):158-69
pubmed: 6066618
Exp Neurol. 2017 Dec;298(Pt A):13-22
pubmed: 28822838
Anal Biochem. 1982 Oct;126(1):131-8
pubmed: 7181105
J Food Sci Technol. 2015 Sep;52(9):5393-407
pubmed: 26344956
Toxins (Basel). 2019 Jul 12;11(7):
pubmed: 31336817
J Biol Chem. 1972 May 25;247(10):3170-5
pubmed: 4623845
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:201-7
pubmed: 26596986
Biosci Rep. 2019 May 15;39(5):
pubmed: 30992387
CNS Neurol Disord Drug Targets. 2011 Nov;10(7):808-19
pubmed: 21999730
J Neurochem. 1996 Jun;66(6):2532-40
pubmed: 8632179
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Nano Today. 2014 Apr 1;9(2):223-243
pubmed: 25132862
Hum Exp Toxicol. 2020 Feb;39(2):159-172
pubmed: 31619074
Neurochem Res. 2013 Jan;38(1):174-85
pubmed: 23086472
Pharmaceutics. 2018 Dec 12;10(4):
pubmed: 30545058
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 15;827(1):65-75
pubmed: 16183338
Biochem Pharmacol. 1961 Jul;7:88-95
pubmed: 13726518
J Epilepsy Res. 2018 Dec 31;8(2):66-73
pubmed: 30809499
Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):591-602
pubmed: 33064168
Nat Rev Neurosci. 2013 May;14(5):337-49
pubmed: 23595016
Toxicol Appl Pharmacol. 2011 Nov 15;257(1):137-47
pubmed: 21925195
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
J Neurosci. 2011 Oct 19;31(42):14850-60
pubmed: 22016518
Chem Biol Interact. 2019 Apr 1;302:108-116
pubmed: 30695686
Int J Biol Macromol. 2019 Jun 1;130:515-526
pubmed: 30826404
Brain Res. 2020 Jul 15;1739:146818
pubmed: 32275911
Int J Biol Macromol. 2020 Jul 1;154:233-245
pubmed: 32171837
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Front Cell Neurosci. 2017 Nov 28;11:377
pubmed: 29234274
Neuropharmacology. 2020 May 1;167:107742
pubmed: 31421074
Neuroscientist. 2012 Aug;18(4):360-72
pubmed: 22235060
Anal Biochem. 1984 Jan;136(1):65-74
pubmed: 6711815
Brain Res. 1999 Feb 13;818(2):575-8
pubmed: 10082851
Lancet Neurol. 2011 Aug;10(8):721-33
pubmed: 21777827
Seizure. 2017 Feb;45:119-124
pubmed: 28012414
Mediators Inflamm. 2014;2014:901902
pubmed: 25197169
Exp Ther Med. 2019 Apr;17(4):3083-3091
pubmed: 30906480
Methods Enzymol. 1984;105:121-6
pubmed: 6727660
Biomolecules. 2020 Mar 18;10(3):
pubmed: 32197322
Pharmacognosy Res. 2018 Jan-Mar;10(1):49-54
pubmed: 29568187
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Prog Neurobiol. 2001 Sep;65(1):1-105
pubmed: 11369436
Oxid Med Cell Longev. 2014;2014:293689
pubmed: 25614776
Front Neurosci. 2019 May 22;13:512
pubmed: 31191222